While company stock is down, and Nuerocrine BioSciences are still reporting a loss of nearly 42 million dollars for the first two quarters of 2008, I find it almost laughable that such companies are crying hard times, in the midst of releasing more and more antagonist drugs. I find it somewhat reassuring though as you read into the article that subjects of the 602 tests seam to be actually liking the effects of this treatment. In addition some patients and investors alike claim that the July 30th end date for the study will lead to even further answers about how such bioscience may one day be able to alleviate the pain of endometriosis for patients. The study was limited to 252 patients. While I am encouraged by the study itself, I am discouraged that only 250 patients are being studied in a controlled environment when there are more then 70 million women in this world suffering from this disease.
Read the report here
August Newsletter will be LATE!
16 years ago
No comments:
Post a Comment